The Defense Department has chosen Advanced Regenerative Manufacturing Institute Inc. to oversee a tissue biofabrication manufacturing innovation facility in Manchester, New Hamsphire, with up to $294 million in public-private investment.
DoD said Wednesday that ARMI will lead the Advanced Tissue Biofabrication Manufacturing USA Institute as part of continuing efforts to help advance U.S. manufacturing and new technology development initiatives.
ATB is part of the Manufacturing USA Institute network and comprised of 87 industrial, academic, government and nonprofit organizations that will work to develop manufacturing processes to repair the cells, tissues and organs of wounded warriors and civilians.
ARMI will collaborate with partners from various disciplines such as cell biology and bioengineering, materials science and computer modeling to develop high-throughput culture and three-dimensional biofabication techniques, the White House said Wednesday.
High-throughput culture systems, 3D biofabrication technologies, bioreactors, storage methodologies, non-destructive evaluation, real-time monitoring and sensing and detection systems are some of the technologies considered mature within the ATB institute.
The ATB facility marks the 12th Manufacturing USA institute in the network.
“The investments we are making in advanced manufacturing, including today’s announcement, will ensure that the innovations needed to develop, manufacture and commercialize cutting-edge processes and materials will happen right here, in America,” said Defense Secretary Ashton Carter.